


UPDATE ON EPIDEMIOLOGY & INFORMATION GENERATING INITIATIVES

Dr Sharon Hutchinson


**Chair, National Information Generating Initiatives
Network**

HCV Epidemiological Landscape (Estimates): Scotland, 2006




* Includes those who have cleared HCV from therapy

Deprivation among persons with HCV in Scotland, compared with other conditions




HCV disease trends


New cases of HCV-related liver failure in Scotland



Number of hospital bed-days associated with HCV-related liver failure in Scotland



Annual number of deaths related to HCV and AIDS in Scotland



* Provisional (based on mid-year data)



Action 19


- Further development of the National Hepatitis C Clinical Database, including the establishment of a Generic Clinical System (GCS)

Progress

- The National Hepatitis C Clinical Database Monitoring Committee (chaired by Prof Peter Hayes) continues to oversee and guide developments.
- An Executive Group (chaired by Dr John Dillon) established to support the Monitoring Committee and co-ordinate the development, procurement and implementation of the GCS.
- Tender for the GCS was advertised in April 2009; appointment of an IT contractor anticipated by August 2009.
- In response to stakeholder feedback, the GCS will be designed to facilitate the management of patients with Hepatitis B, as well as those with Hepatitis C.

Performance indicators related to treatment of HCV in Scotland

- In 2008, approximately **560** HCV infected persons commenced antiviral therapy in Scotland; in excess of the 2008/09 target of 500 treatment initiations.
- Response to HCV antiviral therapy among patients initiated during January 2006 – July 2007 (Data from 8 clinics, N = 484):
 - **Overall sustained viral response: 57%** [range 43-67%]
 - ⇒ For genotypes 2 & 3: **67%**
 - ⇒ For other genotypes: **40%**



Action 20

- Development of a surveillance system to monitor HCV testing practice in Scotland.

Progress

- HPS has consulted with key stakeholder groups:
 - the Scottish Clinical Virology Consultants Group
 - the Scottish Microbiology Forum
- Proposal is to collate HCV testing and diagnosis information through ECOSS.
- The West of Scotland Specialist Virology Centre has agreed to act as a pilot site.
- The survey of laboratories undertaken during Phase I has been repeated to establish the uptake of HCV testing during 2008.




HCV antibody tests in Scotland, 2006 & 2008

	2006	2008
Total HCV antibody tests (from laboratory survey)	61,700	70,600
New HCV antibody positive diagnoses: (from the National Hepatitis C Diagnoses Database)	1,500	1,700

2.4% of all HCV antibody tests were new HCV diagnoses

HCV diagnoses by age in Scotland (to end of 2008)



Action 21

- Development of a data collection system to monitor the provision of injection equipment in Scotland.

Progress

- A steering group has been established by ISD, to oversee the design of a new system to monitor injecting equipment provision.
- A national survey of injection equipment services was undertaken by ISD in 2008:
 - report due for publication in June 2009;
 - the data have contributed to a review of services by NHS Boards.
- ISD proposes to repeat this survey on an annual basis, providing an audit of services against the National Guidelines, until a new system is implemented.
- Consultation with stakeholders on the design of the new system is ongoing.


Action 22

- Annual surveys of HCV prevalence and incidence among IDUs across Scotland.

Progress

- The Needle Exchange Surveillance Initiative (NESI), measuring the prevalence and incidence of HCV among IDUs, has been expanded to cover the 11 NHS Boards in mainland Scotland.
 - First wave of recruitment undertaken during June 2008 to June 2009;
 - In excess of 2,200 IDUs interviewed by mid May in 10/11 NHS Boards;
 - Report is due to be published in November 2009.
- Clinical governance approval obtained to measure HCV prevalence through an unlinked anonymous survey of residual sera from IDUs having a named HIV test in Greater Glasgow & Clyde, Lothian, Tayside and Grampian NHS Boards:
 - Testing of residual sera from IDUs in GG&C for 2006 and 2007 completed;
 - Survey is being rolled out across the remaining 3 NHS Boards.

HCV prevalence among IDUs in Glasgow* (1990-2007)



* Unlinked anonymous HCV testing of residual sera from IDUs having a named HIV test




Action 23

- Survey of HCV prevalence and incidence among prisoners in Scotland.

Progress

- The specification for the study of HCV prevalence and incidence among prisoners in Scotland has been agreed between SPS and the Action Plan Governance Board.
- A tender for the study will be advertised shortly in the Official Journal of the European Union.



Action 24

- Surveys to estimate the prevalence of HCV among
 - i) children in Scotland,
 - ii) people in Scotland who have lived in Pakistan (and, possibly, other South Asian countries)

Progress

- Steering groups for both prevalence surveys have been established.
- Ethical approval obtained for a survey of HCV prevalence among children attending the Glasgow Dental Hospital and School.
- HPS is collaborating with GG&C NHS Board on the design of the survey of people who have lived in Pakistan (and, possibly, other South Asian countries).

Acknowledgements

Action 19

- Members of the National Hepatitis C Clinical Database Monitoring Committee (chaired by Prof Peter Hayes)
- Members of the Executive Group (chaired by Dr John Dillon)

Action 20

- Members of the ECOSS Board (chaired by Dr Anne Eastaway)
- Members of the Scottish Clinical Virology Consultants Group and the Scottish Microbiology Forum

Action 21

- ISD and Members of the ISD Steering Group (chaired by Sita Smith)

Action 22

- Members of the NESI Group (lead by Prof Avril Taylor) and Members of the UK IDU sero and behavioural surveillance Steering Group (chaired by Dr Viv Hope)

Action 23

- SPS (Ruth Parker and Stephen Heller-Murphy)

Action 24

- Members of the Steering Groups for the surveys of children (chaired by Prof Richard Welbury) and of people who have lived in Pakistan (particularly GG&C NHS Board)

Working across Actions:

- Members of the HPS Hepatitis C Programme Team